RT Journal Article
SR Electronic
T1 Detection of neutralising antibodies to SARS coronavirus 2 to determine population exposure in Scottish blood donors between March and May 2020
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2020.04.13.20060467
DO 10.1101/2020.04.13.20060467
A1 Thompson, CP.
A1 Grayson, N.
A1 Paton, R.S.
A1 Bolton, J.
A1 Lourenco, J.
A1 Penman, BS.
A1 Lee, L.
A1 Odon, V.
A1 Mongkolsapaya, J.
A1 Chinnakannan, S.
A1 Dejnirattisai, W.
A1 Edmans, M.
A1 Fyfe, A.
A1 Imlach, C.
A1 Kooblall, K.
A1 Lim, N.
A1 Liu, C.
A1 Lopez-Camacho, C.
A1 McInally, C.
A1 McNaughton, A.L.
A1 Ramamurthy, N.
A1 Ratcliff, J.
A1 Supasa, P.
A1 Sampson, O.
A1 Wang, B.
A1 Mentzer, A.
A1 Turner, M.
A1 Semple, M.G.
A1 Baillie, J.K.
A1 ,
A1 Harvala, H.
A1 Screaton, G.R.
A1 Temperton, N.
A1 Klenerman, P.
A1 Jarvis, L.M.
A1 Gupta, S.
A1 Simmonds, P.
YR 2020
UL http://medrxiv.org/content/early/2020/07/29/2020.04.13.20060467.abstract
AB Background The progression and geographical distribution of SARS coronavirus 2 (SARS-CoV-2) infection in the UK and elsewhere is unknown because typically only symptomatic individuals are diagnosed. We performed a serological study of blood donors in Scotland between the 17th of March and the 18th of May to detect neutralising antibodies to SARS-CoV-2 as a marker of past infection and epidemic progression.Aim To determine if sera from blood bank donors can be used to track the emergence and progression of the SARS-CoV-2 epidemic.Methods A pseudotyped SARS-CoV-2 virus microneutralisation assay was used to detect neutralising antibodies to SARS-CoV-2. The study group comprised samples from 3,500 blood donors collected in Scotland between the 17th of March and 19th of May, 2020. Controls were collected from 100 donors in Scotland during 2019.Results All samples collected on the 17th March, 2020 (n=500) were negative in the pseudotyped SARS-CoV-2 virus microneutralisation assay. Neutralising antibodies were detected in 6/500 donors from the 23th-26th of March. The number of samples containing neutralising antibodies did not significantly rise after the 5th-6th April until the end of the study on the 18th of May. We find that infections are concentrated in certain postcodes indicating that outbreaks of infection are extremely localised. In contrast, other areas remain comparatively untouched by the epidemic.Conclusion These data indicate that sero-surveys of blood banks can serve as a useful tool for tracking the emergence and progression of an epidemic like the current SARS-CoV-2 outbreak.Competing Interest StatementThe authors have declared no competing interest.Funding StatementFunding statement. This work was supported by the Georg & Emily Opel Foundation. This work was supported by the Medical Research Council [grant number MC_PC_19059]. National Institute for Health Research Biomedical Research Centre Funding Scheme (to G.R.S.), the Chinese Academy of Medical Sciences (CAMS) Innovation Fund for Medical Science (CIFMS), China (grant number: 2018-I2M-2-002). PK, PS and G.R.S. is supported as a Wellcome Trust Senior Investigator (grant 095541/A/11/Z, WT109965/MA). PK is an NIHR Senior Investigator. NG was supported via grant to Philip Goulder (WTIA Grant WT104748MA) and a grant to John Frater (Medical Research Council MR/L006588/1). CPT was funded by an ERC research grant UNIFLUVAC and two MRC CiC grants (Ref: BR00140). LNL is supported by a CRUK Cancer Immunology Award (C30332/A23521) to PK.The funders played no role in the design, execution or reporting of the study. RP also supported by funds provided under Professor RW Snow's Wellcome Trust Principal Fellowship (# 212176). ALM is funded by a NIHR Research Capability Funding grant.Author DeclarationsAll relevant ethical guidelines have been followed; any necessary IRB and/or ethics committee approvals have been obtained and details of the IRB/oversight body are included in the manuscript.YesAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data obtained in the study is available from the authors upon request